The investigation, led by Yu Hasegawa of the Women’s Biomedical Research Institute at the Icahn School of Medicine at Mount Sinai, together with colleagues at the University of Maryland School of Medicine and other institutions, focused on bacterial extracellular vesicles, or bEVs. These are nanoscale, membrane-bound packages that bacteria shed continuously, carrying proteins, toxins, DNA, RNA, and fragments of cell-wall components. Far from being inert debris, bEVs act as messengers: they travel through the mucus and fluid lining the vaginal tract, dock onto epithelial and immune cells, and deliver molecular signals that can calm or inflame the host. In effect, they form a communication network layered on top of the microbiome itself, and it is this network that the new work shows is scrambled by antibiotic exposure.

The team worked with three species that define very different vaginal states. Lactobacillus crispatus dominates a healthy vaginal microbiome, classified as Community State Type I, and its presence is associated with low inflammation and protection against infection. By contrast, microbiomes dominated by anaerobes such as Gardnerella vaginalis and Mobiluncus mulieris, known as Community State Type IV, are linked to bacterial vaginosis and to serious downstream consequences, including increased susceptibility to sexually transmitted infections, infertility, and preterm birth. Understanding how these species signal to host tissue, and how treatment alters that signaling, is therefore central to explaining why bacterial vaginosis so often recurs after antibiotic therapy.

To probe this, the researchers grew each species in the laboratory and exposed cultures to three clinically relevant antibiotics, ampicillin, clindamycin, and metronidazole, at doses below the minimum inhibitory concentration, the threshold normally required to stop bacterial growth. This sub-minimal dosing was deliberate: in a real vaginal environment, antibiotic concentrations vary widely across time and space, and bacteria in protected niches frequently experience levels that stress rather than kill them. The team then isolated the vesicles released by treated and untreated cultures and quantified them using nanoparticle tracking analysis, a laser-based technique that counts and sizes individual nanoparticles in suspension.

The isolated vesicles were next applied to laboratory cultures of human epithelial and immune cells, and the inflammatory response was measured with cytokine profiling using multiplex immunoassays, which can quantify dozens of immune signaling molecules simultaneously. The researchers also performed Toll-like receptor pathway analyses. Toll-like receptors are pattern-recognition molecules on the surface of host cells that detect conserved microbial structures such as lipoproteins and flagellin, and they sit at the front line of innate immunity, deciding whether a bacterial signal is interpreted as benign or threatening.

The results were striking and highly specific. Antibiotic exposure significantly enhanced the inflammatory properties of the vesicles, but the effect depended on both the bacterial species and the antibiotic involved. Vesicles from antibiotic-exposed Gardnerella vaginalis cultures provoked elevated cytokine responses in host cells primarily through activation of TLR2, the receptor that recognizes bacterial lipoproteins. Vesicles from Mobiluncus mulieris, meanwhile, stimulated inflammation through both TLR2 and TLR5, the latter being the receptor dedicated to detecting flagellin, the protein that builds bacterial tails. These findings indicate that the drugs do not merely reduce bacterial numbers; they change the molecular cargo and immune visibility of the vesicles the surviving bacteria release.

Perhaps the most unexpected result concerned Lactobacillus crispatus. Vesicles from this beneficial species are typically non-inflammatory, consistent with its role in maintaining a calm vaginal environment. Yet when the cultures were exposed to metronidazole, the workhorse drug for bacterial vaginosis, even at a dose lower than what is used clinically, the resulting vesicles became immunostimulatory. In other words, a treatment intended to restore vaginal health may inadvertently push its most protective resident into producing inflammatory signals, an unintended proinflammatory consequence that could help explain why some patients feel worse before they feel better, and why the microbial ecosystem sometimes fails to settle back into a healthy state after therapy.

The study did not stop at laboratory cultures. Examining human vaginal swabs, the researchers detected bacterial extracellular vesicles directly in patient samples, including vesicles carrying vaginolysin, a toxin characteristic of Gardnerella. Notably, such vesicles were found even in swabs from women whose microbiomes were classified as Community State Type I, dominated by Lactobacillus. This indicates that low-abundance microbes, including potential pathogens, remain transcriptionally active even when they are too scarce to register in standard microbiome profiling, quietly releasing vesicles that continue to shape the local immune environment. The vesicle layer, in other words, preserves a memory of the microbial community that simple bacterial census methods miss.

Taken together, the findings suggest that antibiotics reshape bacterial communication in the vagina through their vesicles, potentially contributing to inflammation, disruption of the epithelial barrier that protects underlying tissue, persistent dysbiosis, and the recurrent infections that plague bacterial vaginosis patients. The authors argue that the work underscores the need for precision antimicrobial strategies that eliminate pathogens while preserving beneficial bacteria and their functional vesicles. Future therapies, they suggest, should account for the ecosystem-wide effects of antibiotics on the vaginal microbiome and on the vesicle-mediated signaling network that connects microbes to host immunity. Given the high recurrence rates of bacterial vaginosis and its links to preterm birth and infection risk, treating the vaginal microbiome as an ecosystem to be managed, rather than a pathogen to be eradicated, may prove a decisive shift in women’s health.

Subject of Research: Antibiotic-driven changes in the immune profiles of bacterial extracellular vesicles from vaginal anaerobes

Article Title: Exposure to antibiotics modifies the immune profiles of bacterial extracellular vesicles from common vaginal anaerobes

Article References: Hasegawa, Y., Swain, O., Rajpal, U., France, M., Ncube, L., Mogno, I., Zierden, H., Ravel, J., & Elovitz, M. A. (2026). Exposure to antibiotics modifies the immune profiles of bacterial extracellular vesicles from common vaginal anaerobes. Microbiome. https://doi.org/10.1186/s40168-026-02510-w

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02510-w

Keywords: vaginal microbiome, bacterial extracellular vesicles, bacterial vaginosis, Gardnerella vaginalis, Lactobacillus crispatus, Mobiluncus mulieris, metronidazole, clindamycin, Toll-like receptors, inflammation, dysbiosis, preterm birth

The presence of bacteria within tumor microenvironments—once considered an anomaly or contamination—is now gaining robust clinical and experimental validation. Intratumoral microbiota appears particularly prevalent in cancers such as pancreatic ductal adenocarcinoma, colorectal carcinoma, and biliary tract malignancies, all notorious for aggressive behavior and poor response to standard treatments. These bacteria may infiltrate tumors via multiple routes, including breaches in mucosal barriers in organs like the colon and lungs, direct tissue invasion, or through hematogenous spread from distant sites such as the oral cavity or gut.

Once nestled within tumors, these microbial communities engage in complex cross-talk with cancer cells, stromal elements, and immune constituents. This interaction exerts multifaceted influences: bacterial secretions can induce genomic instability by generating reactive oxygen species and DNA-damaging toxins. Such genetic insults engender mutations and heterogeneity, thwarting the efficacy of targeted therapies. Moreover, microbial metabolites have emerged as potent epigenetic modulators capable of remodeling chromatin structures and gene expression without altering DNA sequences, thereby subtly steering tumor cell phenotypes toward malignant progression.

The inflammatory milieu of tumors also appears shaped by intratumoral bacteria. Through activation of innate immune receptors—such as Toll-like receptors—these microbes trigger pro-inflammatory signaling networks like NF-κB, fostering a chronic state of tumor-promoting inflammation. Paradoxically, this persistent inflammation recruits immunosuppressive immune cell subsets and subverts the anti-tumor immune response, creating an immunologically “cold” microenvironment where malignant cells can evade immune destruction. This immune modulation further complicates the landscape of therapeutic resistance and metastatic potential.

Metabolically, intratumoral bacteria may recalibrate nutrient availability and metabolic pathways within the tumor niche. By influencing tumor cell energy metabolism and facilitating cellular adaptations to hypoxic and nutrient-poor conditions, bacteria help sustain tumor growth and enable invasion. Additionally, bacterial signaling appears to enhance epithelial–mesenchymal transition and cytoskeletal rearrangements, critical steps that promote tumor motility and metastasis.

Despite these profound insights, clinical management has yet to capitalize on the therapeutic potential uncovered by intratumoral microbiota research. Traditional chemotherapeutics often fail in poor prognosis outcome (PPO) tumors due to multifactorial barriers including fibrosis, hypoxia, and drug resistance, but emerging evidence implicates bacterial presence as a critical but underrecognized factor. Nanomedicine approaches, specifically nanoparticle-based drug delivery systems designed to penetrate tumors more effectively, have shown limited clinical success despite encouraging preclinical data. This discrepancy may stem from fundamental differences in tumor architecture and microbiota composition between animal models and human patients, questioning the universality of phenomena like the enhanced permeability and retention (EPR) effect.

The authors propose a timely and pragmatic shift in treatment paradigms: treating PPO tumors presumptively as bacteria-infected entities from the outset, using regimens that combine classical antibiotics with chemotherapeutic agents. Early animal studies suggest that antibiotics such as ciprofloxacin can reverse bacterial-mediated chemoresistance, notably restoring sensitivity to drugs like gemcitabine. This combined approach could mitigate bacterial interference, reduce inflammation-induced immunosuppression, and improve drug efficacy, potentially representing a clinically deployable solution much sooner than the development of next-generation nanocarriers.

This strategy is not without challenges. Antibiotic stewardship remains paramount to avoid disrupting beneficial microbiomes and accelerating antimicrobial resistance—complications particularly relevant in immunocompromised oncology patients. However, many cancer patients already receive antibiotics prophylactically or therapeutically due to infection risks associated with immune suppression and invasive procedures, creating an existing framework for integrating antibacterial agents into treatment protocols more intelligently.

Beyond immediate treatment considerations, recognizing the bacterial dimension of tumor biology invites a broader reconceptualization of cancer as a multifaceted disease involving not only malignant cells but complex microbial ecosystems influencing tumor evolution, immune dynamics, and therapeutic response. This microbial perspective underscores the urgency of developing clinical diagnostics capable of reliably detecting tumor-associated bacteria in living patients, facilitating stratified and personalized therapeutic approaches.

The review underscores that nanomedicine should not be abandoned but rather contextualized within a nuanced temporal framework. While nanodrug platforms hold promise for enhanced targeting and precision, their clinical maturation may span decades—time that patients with aggressive PPO tumors often lack. Hence, antibiotic-chemotherapy combinations represent a potentially expedient interim measure to improve outcomes while advanced technologies evolve.

Ultimately, this groundbreaking review calls for retrospective analysis of existing clinical data and prospective studies designed to validate the bacterial infection hypothesis in PPO tumors. By systematically interrogating bacterial influences on tumor physiology and treatment resistance, oncology could harness a new axis of intervention that revitalizes the efficacy of well-established therapeutics through informed combinatorial strategies.

This paradigm shift holds profound implications for cancer research and care, highlighting the need for interdisciplinary collaboration among oncologists, microbiologists, pharmacologists, and nanotechnologists. It challenges the field to reconsider dogmatic treatments and embrace the tumor microbiome as a critical determinant of cancer behavior and a fertile target for innovation.

As researchers and clinicians strive to outpace the rapid evolution and complexity of resistant cancers, this integrative view offers renewed hope for transforming despair into actionable solutions. Treating tumors not solely as isolated neoplastic lesions but as ecosystems shaped by microbial inhabitants paves the way toward more durable, personalized, and effective cancer therapies.

Subject of Research:
Not applicable

Article Title:
Poor prognosis outcome tumors, bacteria-infected tumors and nanodrugs: current evidence and hypotheses towards a paradigm change for treatment

News Publication Date:
15-Apr-2026

Web References:
Not provided

References:
10.20892/j.issn.2095-3941.2025.0748

Image Credits:
Cancer Biology & Medicine

Keywords:
Cancer, Intratumoral Microbiota, Tumor Microenvironment, Chemoresistance, Pancreatic Ductal Adenocarcinoma, Colorectal Carcinoma, Biliary Cancers, Nanomedicine, Antibiotics, Tumor Immunology, Cancer Treatment, Tumor Microbiome